Literature DB >> 24952383

Moyamoya syndrome and neurofibromatosis type 1.

Euthymia Vargiami, Evdoxia Sapountzi, Dimitris Samakovitis, Spyros Batzios, Maria Kyriazi, Athanasia Anastasiou, Dimitrios I Zafeiriou1.   

Abstract

Neurofibromatosis type 1 (NF1) is the most prevalent autosomal dominant genetic disorder among humans. NF1 vasculopathy is a significant but underrecognized complication of the disease, affecting both arterial and venous blood vessels of all sizes. Moyamoya syndrome is a cerebral vasculopathy that is only rarely observed in association with NF1, particularly in the pediatric age range. Herein, we report of a 5-year-old female with NF1 and moyamoya syndrome and we briefly review the existing literature.

Entities:  

Mesh:

Year:  2014        PMID: 24952383      PMCID: PMC4104827          DOI: 10.1186/1824-7288-40-59

Source DB:  PubMed          Journal:  Ital J Pediatr        ISSN: 1720-8424            Impact factor:   2.638


Introduction

Neurofibromatosis type 1 (NF1) or von Recklinghausen is the most common neurocutaneous contidion with an autosomal dominant pattern of inheritance. 1/3 of cases are new mutations [1]. This genetic disorder caused by mutations of the NF1 gene which is located on chromosome 17(17q11.2) [1]. Patients with NF1 may present with a variety of central nervous system complaints, such as seizures, learning disability and attention-deficit disorder. Intracranial lesions associated with NF1 include optic gliomas, sphenoid wing dysplasia, “unidentified bright objects” (UBOs) [1,2]. Cerebrovascular lesions such as moyamoya syndrome are rarely seen in NF1 [2]. Herein, we report of a 5-year-old female with NF1 and moyamoya syndrome and we briefly review the existing literature.

Case report

A 5 year-old female was admitted to the hospital with a history of acute right-sided weakness. The physical examination revealed several café-au-lait spots (larger than 0.5 cm) and freckling in the inguinal area and the axillae, thus fulfilling diagnostic criteria for NF1 [1,2]. The neurologic examination demonstrated right spastic hemiplegia with increased muscle tone of upper and low extremities, increased tendon reflexes as well as right facial nerve palsy.Regarding the NF1 work-up, including laboratory investigations, complete blood cell count, blood biochemistry, radiographs of long bones, electroencephalogram, visual and brainstem auditory evoked potentials, echocardiography, abdominal ultrasound and ophthalmologic examination were normal. Brain magnetic resonance imaging (MRI) of the brain, showed multiple small foci of T2 prolongation in the right periventricular white matter, as well as both globus pallidi and cerebellar hemispheres (“unidentified bright objects” -UBOs). These lesions were hypointense on T1-weighted images, did not show any mass effect, and did not enhance after intravenous contrast injection (Figure 1). Also, multiple dot-like flow-void enhancing areas in basal gaglia and thalamus representing lenticulostriade collateral vessels were seen (Figure 2).Magnetic resonance angiography of the brain (MRA) (and subsequent digital subtraction angiography), showed occlusion of the terminal left internal carotid artery (ICA) and severe stenosis of the proximal middle and anterior cerebral arteries, with multiple tiny basal collateral arteries (Figure 3). Anterior circulation was supplied mainly by these lenticulostriate and thalomo-perforator collaterals vessels. The right ICA and the posterior circulation were normal. These findings were considered as typical for moyamoya syndrome. Additional examinations included clotting, thrombophilia screen, iron and folate screen, demonstrated normal findings.
Figure 1

Brain MRI: T2-weighted images (TR/TE 4000/99) showed pathologic areas of increased signal, a. in right basal ganglia (UBO’S), b. Iin the deep white matter of cerebellum, c. in corpus callosum demonstrated typical areas of UBO’S (unidentified bright objects) in NF 1 disease.

Figure 2

Brain MRI: T2-weighted images (TR/TE 4000/99) showed multiple sites empty signal mainly in the left basal ganglia and ipsilateral lunate center in as in the presence of collateral vessels.

Figure 3

MR angiography of the brain (MRA): virgate imaging petrous segment and the proximal portion of the left internal carotid artery and occlusion of the distal vessel.

Brain MRI: T2-weighted images (TR/TE 4000/99) showed pathologic areas of increased signal, a. in right basal ganglia (UBO’S), b. Iin the deep white matter of cerebellum, c. in corpus callosum demonstrated typical areas of UBO’S (unidentified bright objects) in NF 1 disease. Brain MRI: T2-weighted images (TR/TE 4000/99) showed multiple sites empty signal mainly in the left basal ganglia and ipsilateral lunate center in as in the presence of collateral vessels. MR angiography of the brain (MRA): virgate imaging petrous segment and the proximal portion of the left internal carotid artery and occlusion of the distal vessel. After neurosurgical consultation, surgical revascularisation [namely a left encephalo-duroarterio-synangiosis (EDAS)], was carry out electively. The intraoperative and postoperative course was unremarkable. Treatment with aspirin was immediately started and physical and occupational therapy was initiated. At 2-years follow-up her facial weakness had resolved (since 6 months postoperative), but still demonstrates a mild right hemiparesis.

Discussion

NF1 is multisystemic disease, which affect the skin, central nervous system and bone system [1,2]. Its diagnosis is based on the clinical criteria established by the National Institutes of Health (NIH) Consensus Development Conference [3]. For a definitive diagnosis of NF-1, two or more of the following clinical characteristics must be present, six or more café-au-lait spots with a diameter more than 5 mm, two or more neurofibromas, axillary or inguinal freckling, one reticular neurofibroma, two or more Lisch nodules (hamartomas), an optic glioma, skeletal abnormalities, such as sphenoid dysplasia or pseudarthrosis of the tibia and first degree relationship with a patient suffering from NF1 [3]. These criteria are not sensitive to very young children, since many of them may appear gradually over the years, while children over 10 years old who do not meet the criteria are unlikely to suffer from NF1 [3]. NF1 vasculopathy is a significant but under-recognized complication of the disease, affecting arterial and venous blood vessels of all sizes. Although the arterial system is most commonly affected, venous circulation may also be involved [2]. A variety of vascular lesions have been noted in patients with NF1, including occlusion, aneurysm, pseudoaneurysm, ectasia, stenosis, fistula and rupture [4,5]. According to bibliographic data, the internal carotid artery is most commonly affected, followed by middle and posterior cerebral artery. Although rare in childhood, there was extracranial vascular involvement mainly in the renal artery [5]. The main characteristic of vascular lesions in patients with NF-1 is occlusion of the lumen and hyperplasia of the intima wall. Based on microscopic evaluation of the affected vessels, it has been proposed that the vasculopathy of NF-1 patients results from abnormal neurofibromin function that leads to excessive proliferation of vascular smooth muscle cells during normal maintenance of the vessel. Conversely, even though neurofibromin is known to be expressed in vascular smooth muscle cells, little is known about its function relating to controlling endothelial cell proliferation [2,5,6]. The precise mechanisms involved in NF1, the pathogenesis of vasculopathy are poorly understood but are likely related to the function of neurofibromin, the protein product of the NF1 gene [6]. Neurofibromin has been identified in the endothelial layer of bovine and rodent cerebral and renal arteries, as well as the aorta. It has been hypothesized that the loss of neurofibromin expression in endothelial cells may somehow cause vascular smooth muscle cells to proliferate [6]. It has also been suggested that neurofibromin helps maintain the integrity of the endothelial cell layer, and if this integrity is lost because of aberrant neurofibromin, vascular smooth muscle cells could proliferate [2,6]. Moyamoya syndrome is a rare disorder developing by stenosis and occlusion of small anastomotic vessels in distal branches of bilateral internal carotid arteries [7,8]. Nonetheless, its etiology continues to be ill-defined. Moyamoya syndrome is more frequently observed in the Japanese population, with an estimated incidence of one new case per 1,000,000 individuals per year [7]. The clinical findings present with neurological symptoms, whereas ischemic stroke develops in young adults, subarachnoid hemorrhage develops in older patients in moyamoya syndrome [7]. The prevalence of moyamoya syndrome in NF1 patients is estimated at 0.6%, with more than one hundred cases reported in paediatric patients since 1976 (Table 1) [8-43]. Moyamoya syndrome in patients with NF1 is often initially unilateral and often involves anterior vascular territories [43]. Most cases are asymptomatic, however, subsequent clinical and radiologic worsening is likely to occur [40-43]. In children, the clinical debut often implies ischemic events, such as transient ischemic attacks and ischemic infarcts, as well as focal seizures with headache, and intracranial hemorrhage might also be associated [40-43]. When symptoms are present, they include neurological findings such as paresthesia, headache, epileptic seizures, hemianopsia, nystagmus, aphasia, dysphasia and borderline mental level [16,40-43]. There are several lines of evidence indicating that moyamoya syndrome is related to genetic factors in familial cases. The gene abnormality has been detected in chromosome 17q25.2 [44]. NF1 gene is also mapped on chromosome 17q11.2 [2]. Hence, association of NF1 and moyamoya syndrome could be justified by close proximity neighboring of the responsible genes on chromosome 17 [10]. Moyamoya syndrome in NF1 patients is unilateral in up to 30% of cases, but the observation that progression to bilateral disease occurs in 10%–100% of these patients means that our patient may require long-term surveillance, and noninvasive perfusion studies may be helpful for assessment [9,45].
Table 1

Moyamoya syndrome in NF1 paediatric patients since 1976

AuthorsYearStudyN (patients)AgePatients with moyamoya-NF1
Duat-Rodríguez A et al. [42]
2014
Retrospective review
168
 
4
Partha S. G et al. [40]
2013
Retrospective review
312
 
7
Kaas B et al. [43]
2013
Retrospective review
187
 
5
Ghosh, P. S., et al. [10]
2012
 
398
 
15/312 (4,8%)
Luiz G D et al. [41]
2011
Case report
1
8 months
1
Ullrich, N. J. [11]
2011
Case report
 
 
1
Smith, M [12]
2011
Case report
 
18 m boy
1
Lin, N., et al. [13]
2011
Retrospective review 1988-2010
418
9.1y (1-21y)
13
Horiguchi, S., et al. [14]
2011
Case report
1
32y
1
Darrigo Junior, et al. [15]
2011
Case report
 
8 m female
1
King, J. A., et al. [16]
2010
Retrospective review (May 1996-December 2008)
33
< 16y
3
Tan, R. M., S. M. Chng, et al. [17]
2008
Case report
1
7y female
1
Koc, F., et al. [18]
2008
Case report
1
20y female
1
Borhani-Haghighi, A. and B. Sabayan [19]
2008
 
 
 
 
Wintermark, P., et al. [20]
2007
Case report
 
 
1
Ullrich, N. J., et al. [21]
2007
 
 
 
 
Pascual-Castroviejo, I., et al. [22]
2006
 
12
 
1
Desai, S. S., et al. [23]
2006
Review 1967-2002
54
 
14
Fujimura, T., et al. [24]
2004
Case report
 
15y female
 
Scott, R. M., J. L. Smith, et al. [41]
2004
Retrospective review
143
<20y
13
Hug, E. B., et al.[25]
2002
Retrospective review Sep 1991-Aug 1997
27
 
1
El-Koussy, M., et al. [26]
2002
Case report
 
 
1
Rodriguez-Jadraque, R., et al. [27]
2000
Case report
 
9y
1
Serdaroglu, A., et al. [20]
2000
Case report
 
4y female
1
Piovesan, E. J., et al. [28]
1999
Case report
 
51y
1
Fujimoto, K., et al. [29]
1999
Case report
 
49y female
1
Siqueira Neto, J. I., et al. [30]
1998
Case report
 
28y male
1
Hattori, S., et al. [31]
1998
Case report
 
58y female
1
Barrall, J. et al. [32]
1996
Case report
 
19 m male
1
Gorrotxategi, P., et al. [33]
1994
Case report
 
4y male
1
Kestle, J. R., et al. [34]
1994
Retrospective review 1971-1990
47
 
3
Woody, R. C., et al. [35]
1992
Case report
1
3 m male
1
Sobata, E., H. Ohkuma, et al. [36]
1988
Case report
1
28y female
1
Gracia, C. M., et al. [37]
1986
Case report
1
33y female
1
Quest, D. O. et al. [38]
1985
Retrospective review
17
 
1
Sasaki, O., et al. [39]1984Case report238y male
2
29y female
Moyamoya syndrome in NF1 paediatric patients since 1976 The diagnosis of moyamoya syndrome based on neuroimaging control. In patients with moyamoya syndrome, the brain computed tomography (CT) scan frequently shows ischemic and hemorrhagic lesions, although MRI is more helpful in the diagnosis of moyamoya syndrome because the provide greater parenchymal detail [46]. MRA is very useful for diagnosing moyamoya syndrome, with previous studies showing a sensitivity of 73% and a specificity of 100%. Sensitivity increases to 92% when MRA is combined with MRI findings [46]. The diagnosis of moyamoya syndrome in our patient was supported with MRI and MRA, which is standard practice in our clinical routine screening of children with NF1. Most patients with NF-1 associated with vascular lesions are asymptomatic. Early diagnosis and appropriate surgical management are of utmost importance, to improve cerebral hemodynamics and reduce the incidence of subsequent ischemic events. However, close monitoring of these abnormalities is warranted because the long-term outcome of these vascular lesions is unknown. Moreover, early recognition of a cerebral vasculopathy may have helped prevent complications in several of these children [8,47,48]. Surgical intervention has become the treatment of choice for patients with MMS, and particularly surgical revascularization in order to increase the blood flow to the hypoperfused cortex [49-51]. On the index patient, the surgical procedure of choice was EDAS (encephaloduroarteriosynangiosis) and resulted in no further symptoms or brain insults. In conclusion, vasculopathy in NF1 is a potentially serious and underestimated manifestation. MRA screening could be helpful in identified early vascular lesions in asymptomatic NF1 patients. Further studies are needed, in large cohorts of NF1 patients, to better understand the association between these conditions.

Consent

Written informed consent was obtained from the patient’s guardian/parent/next of kin for the publication of this report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

EV acquiered, analysed and interpreted the data and drafted the biggest part of the manuscript. ES: acquired the data and drafted a small part of the manuscript. DS: acquired the data. SB: acquiered the data and critically revised the manuscript. MK: acquired the data. AA: performed and interpreted the neuroradiological studies and critically revised the manuscript. DIZ: critically revised the manuscript for important intellectual content and supervised the study. All authors read and approved the final manuscript.
  49 in total

1.  Renal artery lesions in patients with moyamoya disease: angiographic findings.

Authors:  I Yamada; Y Himeno; Y Matsushima; H Shibuya
Journal:  Stroke       Date:  2000-03       Impact factor: 7.914

Review 2.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

3.  Cerebral vasculopathy in children with neurofibromatosis type 1.

Authors:  Partha S Ghosh; A David Rothner; Todd M Emch; Neil R Friedman; Manikum Moodley
Journal:  J Child Neurol       Date:  2012-04-24       Impact factor: 1.987

4.  Neurofibromatosis, stroke and basilar impression. Case report.

Authors:  E J Piovesan; R H Scola; L C Werneck; V H Zétola; E M Nóvak; F M Iwamoto; L M Piovesan
Journal:  Arq Neuropsiquiatr       Date:  1999-06       Impact factor: 1.420

5.  Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan.

Authors:  M Fukui
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

6.  Ocular ischemic syndrome in a child with moyamoya disease and neurofibromatosis.

Authors:  J L Barrall; C G Summers
Journal:  Surv Ophthalmol       Date:  1996 May-Jun       Impact factor: 6.048

7.  Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.

Authors:  T Yamauchi; M Tada; K Houkin; T Tanaka; Y Nakamura; S Kuroda; H Abe; T Inoue; K Ikezaki; T Matsushima; M Fukui
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

Review 8.  [Severe stenosis of the internal carotid artery and intracerebral hematoma associated with neurofibromatosis type 1: a case report].

Authors:  K Fujimoto; T Shimomura; Y Okumura
Journal:  No Shinkei Geka       Date:  1999-01

9.  Moyamoya disease with concurrent von Recklinghausen's disease and cerebral arteriovenous malformation.

Authors:  S Hattori; H Kiguchi; T Ishii; T Nakajima; H Yatsuzuka
Journal:  Pathol Res Pract       Date:  1998       Impact factor: 3.250

10.  [Moya-moya disease in a child with multiple malformations].

Authors:  P Gorrotxategi; M J Reguilón; R Gaztañaga; J Hernández Abenza; Y Albisu
Journal:  Rev Neurol       Date:  1995 Mar-Apr       Impact factor: 0.870

View more
  9 in total

1.  Moyamoya syndrome associated with neurofibromatosis type 1 in a pediatric patient.

Authors:  Natália Battisti Serafini; Cássio Battisti Serafini; Alanna Santoro Vinhas; Marcio Barbosa Godinho
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

Review 2.  [Neurofibromatosis type 1 : From diagnosis to follow-up].

Authors:  Rebecca Anders; Franz Wolfgang Hirsch; Christian Roth
Journal:  Radiologie (Heidelb)       Date:  2022-09-07

Review 3.  Neurovascular manifestations of connective-tissue diseases: A review.

Authors:  Sarasa T Kim; Waleed Brinjikji; Giuseppe Lanzino; David F Kallmes
Journal:  Interv Neuroradiol       Date:  2016-08-10       Impact factor: 1.610

4.  Arterial input function and gray matter cerebral blood volume measurements in children.

Authors:  Stephanie B Withey; Jan Novak; Lesley MacPherson; Andrew C Peet
Journal:  J Magn Reson Imaging       Date:  2015-10-30       Impact factor: 4.813

Review 5.  Phakomatoses and cutaneous manifestations associated with moyamoya disease and syndrome.

Authors:  Maja Tomaszewska; Lidia Strzelczuk-Judka; Danuta Ostalska-Nowicka; Katarzyna Jończyk-Potoczna
Journal:  Postepy Dermatol Alergol       Date:  2021-01-06       Impact factor: 1.837

6.  Spinal Muscular Atrophy Type IIIb Complicated by Moyamoya Syndrome: A Case Report and Literature Review.

Authors:  Jing Li; Xin Li; Liqun Wang; Guode Wu
Journal:  Front Cell Neurosci       Date:  2022-02-01       Impact factor: 5.505

7.  A Pleural Solitary Fibrous Tumor, Multiple Gastrointestinal Stromal Tumors, Moyamoya Disease, and Hyperparathyroidism in a Patient Associated with NF1.

Authors:  Yoko Yamamoto; Ken Kodama; Shigekazu Yokoyama; Masashi Takeda; Shintaro Michishita
Journal:  Case Rep Surg       Date:  2015-09-13

8.  Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome.

Authors:  Alessandra D'Amico; Lorenzo Ugga; Sirio Cocozza; Sara Maria Delle Acque Giorgio; Domenico Cicala; Claudia Santoro; Daniela Melis; Giuseppe Cinalli; Arturo Brunetti; Sabina Pappatà
Journal:  Neurol Sci       Date:  2020-07-10       Impact factor: 3.307

Review 9.  Western Moyamoya Phenotype: A Scoping Review.

Authors:  Raphael Miller; Santiago R Unda; Ryan Holland; David J Altschul
Journal:  Cureus       Date:  2021-11-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.